Abstract
Cutaneous lymphomas (CLs) are a heterogeneous group of lymphoproliferative cutaneous neoplasms that in many cases cannot be cured by standard radio- and chemotherapy. Immunotherapy holds promise for a well tolerated treatment approach that allows long-time disease control. Unspecific immunotherapy such as IFNs are successfully used in cutaneous T-cell lymphomas (CTCLs). Antibiotic treatment is often effective in cutaneous B-cell lymphomas (CBCLs). New treatment approaches include fusion toxins and chimeric monoclonal antibodies (mAbs) such as rituximab for CBCLs. The identification of tumour antigens in CTCLs renders these diseases susceptible for vaccination approaches.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
